Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
compasspathways.com

See what CB Insights has to offer

Founded Year

2016

Stage

IPO | IPO

Total Raised

$113M

Date of IPO

9/18/2020

Market Cap

1.28B

Stock Price

36.83

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) develops psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.

Compass Pathways Headquarter Location

3rd Floor, 1 Ashley Road

Altrincham, England, WA14 2DT,

United Kingdom

Latest Compass Pathways News

Drug Development Startup Cybin Is Listed on NYSE’s Small Cap Market

Jul 23, 2021

By Nicholas Say Nicholas Say has been verified by Muck Rack's editorial team Cybin, a psychedelic therapeutics startup, has passed conditional listing approval on the New York Stock Exchange’s small-cap equity market. Doug Drysdale, CEO of the Toronto-based biotech startup said, “Conditional listing approval on the NYSE American is an important milestone in Cybin’s growth journey. We expect expanded access to investors to further fuel our mission to […] / share Published on July 23, 2021 Cybin, a psychedelic therapeutics startup, has passed conditional listing approval on the New York Stock Exchange’s small-cap equity market. “Conditional listing approval on the NYSE American is an important milestone in Cybin’s growth journey. We expect expanded access to investors to further fuel our mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions.” The NYSE’s small-cap equity market is previously known as the American Stock Exchange. In addition, the company’s listing still has to wait for final approval by the NYSE American. Cybin is now studying using psilocybin, the psychedelic compound in “magic mushrooms”, to treat patients with Major Depressive Disorder. As such, a phase two clinical trial on its dissolvable oral strip will be commenced at the University of the West Indies Hospital in Jamaica this year. Psilocybin is a tryptamine connecting to serotonin receptor 5-HT2A in the brain. Psilocybin can cause profound changes in consciousness if used at certain doses. Besides, studies in academic institutions also have found the potential of psychedelic drugs in treating mental health disorders, including certain types of depression. Meanwhile, the startup is also working on novel molecules based on other psychedelic compounds. One of them is a modified version of a short-acting tryptamine for treating alcoholism. Studying psychedelic adoption is increasing with the launch of many startups involved in this area. Both the U.K.-based biotech company Nasdaq-listed Compass Pathways and nonprofit Usona have received breakthrough therapy designation from the U.S. Food and Drug Administration for psilocybin therapies. MindMed company is examining the use of LSD for anxiety and a modified version of ibogaine for the treatment of an opioid-use disorder. Another company like Berlin-based Atai Life Sciences also has listed on the Nasdaq. According to data released by the Multidisciplinary Association for Psychedelic Studies studying MDMA-assisted therapy for post-traumatic stress disorder at its phase three clinical trial, while 67% of participants who received three treatments no longer qualified for a PTSD diagnosis, 88% experienced a clinically meaningful reduction in symptoms. Tags

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Compass Pathways

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Compass Pathways is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

P

Psychedelics

205 items

G

Game Changers 2020

36 items

Our selected startups are high-momentum companies pioneering technology with the potential to transform society and economies for the better.

B

Biopharmaceuticals

5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Compass Pathways Patents

Compass Pathways has filed 3 patents.

The 3 most popular patent topics include:

  • Entheogens
  • Psilocybe
  • Psychedelic tryptamine carriers
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/2/2020

3/16/2021

Psychoactive fungi, Psychedelic tryptamine carriers, Entheogens, Psilocybe, Psychiatric diagnosis

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/2/2020

00/00/0000

00/00/0000

Grant Date

3/16/2021

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Psychoactive fungi, Psychedelic tryptamine carriers, Entheogens, Psilocybe, Psychiatric diagnosis

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Compass Pathways Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Compass Pathways Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.